Compare PROF & PSNYW Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PROF | PSNYW |
|---|---|---|
| Founded | N/A | 2017 |
| Country | Canada | Sweden |
| Employees | N/A | 1686 |
| Industry | Medical/Dental Instruments | Auto Manufacturing |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 244.6M | 290.9M |
| IPO Year | 2017 | N/A |
| Metric | PROF | PSNYW |
|---|---|---|
| Price | $6.80 | $2.50 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 59.2K | 5.8K |
| Earning Date | 05-07-2026 | 03-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 25.89 | N/A |
| EPS | ★ 0.19 | N/A |
| Revenue | $16,098,000.00 | ★ $2,034,261,000.00 |
| Revenue This Year | $92.40 | N/A |
| Revenue Next Year | $64.10 | $79.49 |
| P/E Ratio | $34.32 | ★ N/A |
| Revenue Growth | ★ 50.73 | N/A |
| 52 Week Low | $3.92 | $0.14 |
| 52 Week High | $8.95 | $7.50 |
| Indicator | PROF | PSNYW |
|---|---|---|
| Relative Strength Index (RSI) | 45.71 | 37.23 |
| Support Level | $6.47 | $0.20 |
| Resistance Level | $7.06 | $3.50 |
| Average True Range (ATR) | 0.33 | 0.24 |
| MACD | -0.01 | -0.02 |
| Stochastic Oscillator | 29.69 | 20.62 |
Profound Medical Corp is a commercial-stage medical device company focused on the development and marketing of AI-powered, MRI-guided, incision-free therapies for the ablation of diseased tissue. The company's flagship product, the TULSA-PRO system, combines real-time MRI, robotically-driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. Its platform technologies combine imaging, robotic control, and ultrasound-based thermal ablation for the treatment of prostate conditions. The company generates revenue through the sale of capital equipment and recurring sales of single-use devices and related services used in patient treatments.
Polestar Automotive Holding UK PLC is a pure play, premium electric car brand, designing performance cars engineered to excite consumers and drive change. It believes that it defines market standards in design, innovation and sustainability. It is determined to improve society by accelerating the shift to sustainable mobility. The company conducts its business as one operating segment with primary commercial operations in Europe, North America, Asia Pacific and various importer markets. The company generates majority of revenue from United Kingdom.